Semaglutide
Also known as: Ozempic, Wegovy, Rybelsus
Overview
Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. Clinical trials show average weight loss of 15-17% body weight. It is currently one of the most widely prescribed weight loss medications globally.
How it works
Mimics endogenous GLP-1 by binding to GLP-1 receptors in the pancreas, brain, and gut. Increases insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric emptying, and acts centrally to reduce appetite and food intake.
Primary uses
- Fat loss
- Type 2 diabetes
- Appetite suppression
- Cardiovascular risk reduction
- Blood sugar regulation
What to expect
Based on reported user experiences and available research, here is a general timeline of effects:
Days 1–14
- Appetite suppression begins within days of the first dose
- Some nausea is common early on — typically resolves within 2-4 weeks
Days 14–56
- Consistent appetite reduction and slower gastric emptying are established
- Weight loss of 1-3kg is typical in the first month
- Blood sugar control is measurably improving
Days 56–168
- Average weight loss of 10-15% is typical at 3-6 months
- Cardiovascular benefit markers are improving
- Dose escalation may be appropriate — review with your provider
Days 168–999
- Long-term cardiovascular protection is one of semaglutide's strongest benefits
- Sustained weight loss maintenance requires continued use
- Consider reviewing your dose and goals with your provider
Storage and preparation
Store at 2-8°C refrigerated. Do not freeze. Once in use, pens can be kept at room temperature below 30°C for up to 56 days.
Available as pre-filled pen — no reconstitution required. Research vials: reconstitute with bacteriostatic water. 3mg vial with 3ml BAC water gives 1mg/ml.
Research
The following studies are available via PubMed:
Track your compound stack in Lymity
Log doses, track cycles, and see your timeline benefits in the app